Wish to keep on prime of the science and politics driving biotech right this moment? Enroll to get our biotech publication in your inbox.
Right this moment, we uncover the extent of low-quality generic most cancers medicines disseminated globally, see ACIP put together to boost new questions on vaccines authorized way back, and extra.
The necessity-to-know this morning
- Incyte introduced the retirement of CEO Hervé Hoppenot after 11 years on the firm. Invoice Meury was appointed Incyte’s new CEO. Meury was most lately CEO of Anthos Therapeutics, which was acquired by Novartis. Previous to that, he labored at Karuna Therapeutics, which was acquired by Bristol Myers Squibb.
- Altimmune’s inventory value dropped by greater than half in early buying and selling after the corporate introduced disappointing outcomes from a research of its GLP-1/glucagon focused drug in MASH. The drug, referred to as pemvidutide, failed to point out a statistically vital enchancment in liver fibrosis in comparison with a placebo.
Generic most cancers medicine used all over the world fail high quality checks, investigation exhibits
A sweeping investigation has uncovered that important generic chemotherapy medicine — utilized in over 100 international locations to deal with widespread cancers — are failing high quality checks, leaving sufferers susceptible to ineffective remedy and poisonous unintended effects. One in 5 samples contained dangerously inaccurate ranges of lively components, based on a report from The Bureau of Investigative Journalism — with some capsules holding as little as 1 / 4 of what the label promised. Others contained an excessive amount of.
